The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Functional fitness of CAR T-cells in the bone marrow following durcabtagene autoleucel in RRMM
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the functional fitness of CAR T-cells in the bone marrow following anti-BCMA durcabtagene autoleucel in relapsed/refractory multiple myeloma (RRMM). Dr Munshi highlights characteristics of CAR T-cells that may predict long-term outcomes. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a study a part of durcabtagene which is a BCMA targeting CAR T-cell which was produced with a unique method where CAR T-cell was produced within a two-day time so very quick production. Utilizing this T-cell maintain their T memory and T stem cell memory phenotype and it has been incredibly effective and we have previously shown that almost 100% response rate using this CAR T-cell. In the study presented here we are looking at the functionality of those CAR T-cells and what we show that patients who respond and have a sustained two-year remission or more have a certain characteristics of their CAR T-cell...
This is a study a part of durcabtagene which is a BCMA targeting CAR T-cell which was produced with a unique method where CAR T-cell was produced within a two-day time so very quick production. Utilizing this T-cell maintain their T memory and T stem cell memory phenotype and it has been incredibly effective and we have previously shown that almost 100% response rate using this CAR T-cell. In the study presented here we are looking at the functionality of those CAR T-cells and what we show that patients who respond and have a sustained two-year remission or more have a certain characteristics of their CAR T-cell. These CAR T-cells population have decreased T regulatory cell. CAR T-cells have more activation markers, CD38, CD28, CD27, et cetera. So they’re more activated. They also have a less apoptosis. So TIM3 is down regulated. And finally, we see presence of some inflammatory cytokines such as IL-2, granzyme, and also change in IL-10. And so what we are defining is that this very effective CAR T-cell has certain characteristics which predicts a long-term outcome in this patient population so over time this can become a predictive marker for CAR T-cell efficiency and persistence and survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
